Patents by Inventor Beatrice Mis
Beatrice Mis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8323638Abstract: Disclosed is a method of treating a wound comprising applying a composition to a wound site on a patient in need of wound treatment, wherein the composition comprises mitotically inactive allogeneic cells that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6 IL-8, TGF?, and TNF?, and wherein the cells are keratinocytes or fibroblasts, or mixtures thereof.Type: GrantFiled: February 8, 2012Date of Patent: December 4, 2012Assignee: DFB Technology Holdings, LLCInventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20120134962Abstract: Disclosed is a method of treating a wound comprising applying a composition to a wound site on a patient in need of wound treatment, wherein the composition comprises mitotically inactive allogeneic cells that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, and wherein the cells are keratinocytes or fibroblasts, or mixtures thereof.Type: ApplicationFiled: February 8, 2012Publication date: May 31, 2012Applicant: DFB TECHNOLOGY HOLDINGS, LLCInventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Patent number: 8137965Abstract: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial.Type: GrantFiled: December 14, 2010Date of Patent: March 20, 2012Assignee: DFB Technology Holdings, LLCInventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20110083987Abstract: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial.Type: ApplicationFiled: December 14, 2010Publication date: April 14, 2011Applicant: DFB TECHNOLOGY HOLDINGS, LLCInventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Patent number: 7879605Abstract: Disclosed is a composition comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-ID, IL-6, IL-8, TGF?, and TNF? and an extracellular matrix comprising alginate, wherein the cells are allogeneic and mitotically inactive.Type: GrantFiled: September 18, 2009Date of Patent: February 1, 2011Assignee: DFB Technology Holdings, LLCInventors: Eric Holland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Patent number: 7700351Abstract: Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers.Type: GrantFiled: October 21, 2008Date of Patent: April 20, 2010Assignee: DFB Pharmaceuticals, Inc.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20100068281Abstract: Disclosed is a composition comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF? and an extracellular matrix comprising alginate, wherein the cells are allogeneic and mitotically inactive.Type: ApplicationFiled: September 18, 2009Publication date: March 18, 2010Applicant: DFB PHARMACEUTICALS, INC.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20090232791Abstract: Disclosed is a kit comprising a first component comprising fibrinogen, aprotinin, and a buffered solution, and a second component comprising, fibroblasts, keratinocytes, thrombin, glycerol, human serum albumin, and a buffered solution, wherein the first and second components are comprised in separate sterile containers.Type: ApplicationFiled: October 21, 2008Publication date: September 17, 2009Applicant: DFB PHARMACEUTICALS, INC.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Patent number: 7449333Abstract: The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.Type: GrantFiled: September 5, 2003Date of Patent: November 11, 2008Assignee: DFB Pharmaceuticals, Inc.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Patent number: 7144729Abstract: The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.Type: GrantFiled: December 19, 2002Date of Patent: December 5, 2006Assignee: DFB Pharmaceuticals, Inc.Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20060121002Abstract: The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.Type: ApplicationFiled: September 5, 2003Publication date: June 8, 2006Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20030165482Abstract: The present invention provides the use and composition of matter of angiogenic or other growth/cytokine factors expressed by mixtures of allogeneic human cell strains or lines of various types and stages of differentiation. Also provided are unencapsulated preparations (mixed with or applied to extracellular matrix material or synthetic biocompatible substances) for the purpose of temporary application to wounds or defects in the skin or other tissues for the restoration of blood supplying connective tissue to enable organ-specific cells to reestablish organ integrity as well as to inhibit excessive scar formation.Type: ApplicationFiled: December 19, 2002Publication date: September 4, 2003Inventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch